← Back to Search


MRI Risk Maps for Prostate Cancer Diagnosis

Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial looks at a software to analyze prostate images. Involves 1-2 biopsies, 1 MRI. Follow-up over 12 months.

Who is the study for?
This trial is for men who are suspected to have prostate cancer or already diagnosed and referred for an MRI of the prostate. They must be able to give written consent and follow study procedures. It's not open to those under 18, prisoners, anyone previously treated for prostate cancer, or with psychiatric disorders affecting consent.Check my eligibility
What is being tested?
Researchers are testing a new software tool designed to improve the analysis of MRI images of the prostate. The goal is to see if this Risk Map Decision Support System can help diagnose prostate cancer more accurately using targeted biopsy guided by MRI.See study design
What are the potential side effects?
Potential side effects may include discomfort from the MRI procedure, risks associated with biopsies like infection or bleeding, and possible anxiety related to undergoing diagnostic tests.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Decision Map Tool Compared to Oncologists

Trial Design

1Treatment groups
Experimental Treatment
Group I: All Participants (Single Arm)Experimental Treatment3 Interventions
All participants in this trial will be provided with routine instructions and precaution information before starting the magnetic resonance (MRI) scan. After the MRI, participants will undergo an MRI-guided fusion biopsy of the prostate as ordered by their doctor. During this prostate MRI-guided fusion biopsy, the research team will obtain tissue from up to two additional biopsy targets selected by the Risk Map DSS tool. Ultimately, the clinical radiologist will make the final decision on the targets to be biopsied.
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnetic Resonance Imaging (MRI)
Completed Phase 4

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor
1,017 Previous Clinical Trials
734,339 Total Patients Enrolled
21 Trials studying Prostate Cancer
8,160 Patients Enrolled for Prostate Cancer
Aytekin Oto, MDStudy ChairUniversity of Chicago Medicine Comprehensive Cancer Center
2 Previous Clinical Trials
149 Total Patients Enrolled
1 Trials studying Prostate Cancer
100 Patients Enrolled for Prostate Cancer

Media Library

Magnetic Resonance Imaging (MRI) Guided Biopsy (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05710380 — N/A
Prostate Cancer Research Study Groups: All Participants (Single Arm)
Prostate Cancer Clinical Trial 2023: Magnetic Resonance Imaging (MRI) Guided Biopsy Highlights & Side Effects. Trial Name: NCT05710380 — N/A
Magnetic Resonance Imaging (MRI) Guided Biopsy (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05710380 — N/A
~110 spots leftby May 2026